Skip to main content

Advertisement

Log in

A new oral testosterone undecanoate formulation

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Testosterone undecanoate has been available on the market for more than 20 years. This testosterone ester is used worldwide for oral treatment of male hypogonadism. So far, testosterone undecanoate has been dissolved in oleic acid, leading to inconvenient storage conditions. It will now be available in a new formulation with castor oil and propylene glycol laurate instead of oleic acid, thus improving storage conditions markedly (stable at room temperature for approximately 3 years). Pharmacokinetic and pharmacodynamic studies have demonstrated bioequivalence of the old and the new formulation of testosterone undecanoate. Therefore, the results of studies that were performed with the old formulation can be transferred to the clinical use of the new formulation. Controlled studies have shown its efficacy in the treatment of symptoms associated with reduced serum testosterone levels. In these cases testosterone undecanoate improves bone mineral density, quality of life, muscle mass, libido and mood. Further studies will help evaluate the efficacy and safety of the new formulation in the treatment of elderly men with late-onset hypogonadism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Abdelmassih R, Dhont M, Comhaire F (1992) Pilot study with 120 mg Andriol treatment for couples with a low fertilization rate during in-vitro fertilization. Hum Reprod 7:267–268

    CAS  PubMed  Google Scholar 

  2. Albanese A, Kewley GD, Long A, Pearl KN, Robins DG, Stanhope R (1994) Oral treatment for constitutional delay of growth and puberty in boys: a randomised trial of an anabolic steroid or testosterone undecanoate. Arch Dis Child 71:315–317

    CAS  PubMed  Google Scholar 

  3. Anawalt BD, Amory JK, Wang C, Swerdloff RS, Dobs AS, Meikle AW, Elbers JMH, Houwing NS (2002) A pharmacokinetic study of oral testosterone undecanoate (Org 538). J Androl [Suppl]: 37

  4. Bagchus WM, Mink CPA, Maris F, Houwing NS (2001) Bioequivalence of Andriol® and Andriol® Testocaps™. Aging Male 4:259

    Google Scholar 

  5. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS (2003) Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 23:319–325

    CAS  PubMed  Google Scholar 

  6. Boyanov MA, Boneva Z, Christov VG (2003) Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6:1–7

    CAS  PubMed  Google Scholar 

  7. Brown DC, Butler GE, Kelnar CJ, Wu FC (1995) A double blind, placebo controlled study of the effects of low dose testosterone undecanoate on the growth of small for age, prepubertal boys. Arch Dis Child 73:131–135

    CAS  PubMed  Google Scholar 

  8. Butler GE, Sellar RE, Walker RF, Hendry M, Kelnar CJ, Wu FC (1992) Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab 75:37–44

    CAS  PubMed  Google Scholar 

  9. Comhaire F (1990) Treatment of idiopathic testicular failure with high-dose testosterone undecanoate: a double-blind pilot study. Fertil Steril 54:689–693

    CAS  PubMed  Google Scholar 

  10. Comhaire F, Schoonjans F, Abdelmassih R, Gordts S, Campo R, Dhont M, Milingos S, Gerris J (1995) Does treatment with testosterone undecanoate improve the in-vitro fertilizing capacity of spermatozoa in patients with idiopathic testicular failure? (results of a double blind study). Hum Reprod 10:2600–2602

    CAS  PubMed  Google Scholar 

  11. Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11:247–264

    CAS  PubMed  Google Scholar 

  12. Cutolo M, Balleari E, Giusti M, Intra E, Accardo S (1991) Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 34:1–5

    CAS  PubMed  Google Scholar 

  13. Geurts TBP, Coelingh Bennink HJT (2000) Testosterone replacement therapy—testosterone undecanoate (Andriol®). J Urol Urogynaekol 1[Special Edition]: 24–35

  14. Gooren LJG (1994) A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 15:212–215

    CAS  PubMed  Google Scholar 

  15. Gregoriou O, Papadias C, Gargaropoulos A, Konidaris S, Kontogeorgi Z, Kalampokas E (1993) Treatment of idiopathic infertility with testosterone undecanoate. A double blind study. Clin Exp Obstet Gynecol 20:9–12

    CAS  PubMed  Google Scholar 

  16. Hajjar RR, Kaiser FE, Morley JE (1997) Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 82:3793–3796

    CAS  PubMed  Google Scholar 

  17. Horst HJ, Höltje WJ, Dennis M, Coert A, Geelen J, Voigt KD (1976) Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr 54:875–879

    CAS  PubMed  Google Scholar 

  18. Jeantils V, Nguyen G, Bacle F, Thomas M, Krivitsky A (1993) Weight gain under testosterone undecanoate in AIDS. Therapie 48:71–72

    CAS  PubMed  Google Scholar 

  19. Jockenhovel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Muller-Wieland D, Krone W (1999) Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 48:590–596

    CAS  PubMed  Google Scholar 

  20. Kalinchenko SY, Kozlow GI, Gontcharow, Katsiya GV (2003) Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 6:94–99

    PubMed  Google Scholar 

  21. Kloer H, Hoogen H, Nieschlag E (1980) Trial of high-dose testosterone undecanoate in treatment of male infertility. Int J Androl 3:121–129

    CAS  PubMed  Google Scholar 

  22. Li JY, Zhu JC, Dou JT, Bai WJ, Deng SM, Li M, Huang W, Jin H (2002) Effects of androgen supplementation therapy on partial androgen deficiency in the aging male: a preliminary study. Aging Male 5:47–51

    CAS  PubMed  Google Scholar 

  23. Luisi M, Franchi F (1980) Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J Endocrinol Invest 3:305–308

    Google Scholar 

  24. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16:991–997

    CAS  PubMed  Google Scholar 

  25. Morales A, Lunenfeld B (2002) Investigation, treatment and monitorino of late-onset hypogonadism in males. Aging Male 5:74–86

    CAS  PubMed  Google Scholar 

  26. Papadimas J, Bili E, Papadopoulo E, Spanos E, Tarlatzis B, Kokkas B (1996) Testosterone undecanoate versus mesterolone in hypogonadal patients. Rev Clin Pharmacol Pharmacokinet Int 10:3–8

    CAS  Google Scholar 

  27. Park NC, Yan BQ, Chung JM, Lee KM (2003) Oral testosterone undecanoate (Andriol®) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male 6:86–93

    CAS  PubMed  Google Scholar 

  28. Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV (2002) Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl 25:119–125

    Article  CAS  PubMed  Google Scholar 

  29. Pusch HH (1989) Oral treatment of oligozoospermia with testosterone-undecanoate: results of a double-blind-placebo-controlled trial. Andrologia 21:76–82

    CAS  PubMed  Google Scholar 

  30. Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhövel F (2003) Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 60:21–28

    Article  CAS  PubMed  Google Scholar 

  31. Schürmeyer T, Wickings EJ, Freischem CW, Nieschlag E (1983) Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol 102:456–462

    PubMed  Google Scholar 

  32. Shackleford DM, Faassen WA, Houwing N, Lass H, Edwards GA, Porter CJH, Charman WN (2003) The contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two Andriol® formulations in conscious lymph-duct cannulated dogs. J Pharmacol Exp Ther 306:1–9

    Article  PubMed  Google Scholar 

  33. Skakkebaek NE, Bancroft J, Davidson DW, Warner P (1981) Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 14:49–61

    Google Scholar 

  34. Tan RS, Pu SJ (2003) A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer’s disease. Aging Male 6:13–17

    CAS  PubMed  Google Scholar 

  35. Täuber U, Schröder K, Düsterberg B, Matthes H (1986) Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur J Drug Metab Pharmacokinet 11:145–149

    PubMed  Google Scholar 

  36. Uyanik BS, Ari Z, Gumus B, Yigitoglu MR, Arslan T (1997) Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Jpn Heart J 38:73–82

    CAS  PubMed  Google Scholar 

  37. Vandekerckhove P, Lilford R, Vail A, Hughes E (2000) Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2:CD000150

    PubMed  Google Scholar 

  38. Vermeulen A, Kaufman JM (2002) Diagnosis of hypogonadism in the aging male. Aging Male 5:170–176

    CAS  PubMed  Google Scholar 

  39. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol 58A: 618–625

    CAS  Google Scholar 

  40. Wu S, Weng X (1992) Therapeutic effect of andriol on serum lipids and apolipoproteins in elderly male coronary heart disease patients. Chin Med Sci J 7:137–141

    CAS  PubMed  Google Scholar 

  41. Wu SZ, Weng XZ (1993) Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl) 106:415–418

    Google Scholar 

  42. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E (2003) Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 88:2049–2054

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frank-Michael Köhn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Köhn, FM., Schill, WB. A new oral testosterone undecanoate formulation. World J Urol 21, 311–315 (2003). https://doi.org/10.1007/s00345-003-0372-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-003-0372-x

Keywords

Navigation